{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:41:08Z","timestamp":1775713268572,"version":"3.50.1"},"reference-count":100,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:p>Autoimmune bullous diseases can be intraepidermal (pemphigus group of disorders) or subepidermal (pemphigoid group of disorders). The treatment of these disorders chiefly comprises corticosteroids and immunosuppressant adjuvants like azathioprine and mycophenolate mofetil. Autoantibodies are the main mediators of these diseases. Rituximab, a chimeric anti-CD20 monoclonal antibody targeting B-cells, has emerged as an excellent treatment option for refractory pemphigus vulgaris in the last decade. Since then, many new biologics have been proposed\/explored for managing autoimmune bullous diseases. These hold potential for greater efficacy and lesser adverse effects than conventional immunosuppressants. In this review, we discuss the role of various biologics in the treatment of autoimmune bullous diseases, followed by a brief discussion on the drawbacks to their use and new developments in this area.<\/jats:p>","DOI":"10.25259\/ijdvl_886_19","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T05:15:20Z","timestamp":1625721320000},"page":"611-620","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Biologics in autoimmune bullous diseases: Current scenario"],"prefix":"10.25259","volume":"87","author":[{"given":"Anuradha","family":"Bishnoi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipankar","family":"De","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Handa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"10.25259\/IJDVL_886_19\/ref-1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4103\/ijd.IJD_199_17","article-title":"Shifting focus in the therapeutics of immunobullous disease","volume":"62","author":"De","year":"2017","journal-title":"Indian J Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-2","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-018-0976-5","article-title":"Targeted therapies for autoimmune bullous diseases: Current status","volume":"78","author":"Amber","year":"2018","journal-title":"Drugs"},{"key":"10.25259\/IJDVL_886_19\/ref-3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/exd.12229","article-title":"Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris","volume":"22","author":"Amber","year":"2013","journal-title":"Exp Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1159\/000448031","article-title":"Assessment of the effects of rituximab monotherapy on different subsets of circulating T-regulatory cells and clinical disease severity in severe pemphigus vulgaris","volume":"232","author":"Bhattacharjee","year":"2016","journal-title":"Dermatology"},{"key":"10.25259\/IJDVL_886_19\/ref-5","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3389\/fimmu.2018.00622","article-title":"B cell modulation strategies in autoimmune diseases: New concepts","volume":"9","author":"Musette","year":"2018","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_886_19\/ref-6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Auto Immun Highlights"},{"key":"10.25259\/IJDVL_886_19\/ref-7","first-page":"1338","article-title":"Successful treatment of pemphigus vulgaris withofatumumab","volume":"17","author":"Rapp","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamadermatol.2014.1939","article-title":"Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris","volume":"150","author":"Ellebrecht","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-9","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/bjh.15132","article-title":"New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies","volume":"180","author":"Meyer","year":"2018","journal-title":"Br J Haematol"},{"key":"10.25259\/IJDVL_886_19\/ref-10","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1517\/14712598.2014.915937","article-title":"Epratuzumab for systemic lupus erythematosus","volume":"14","author":"Antoniu","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.25259\/IJDVL_886_19\/ref-11","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.autrev.2015.07.013","article-title":"The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus","volume":"14","author":"D\u00f6rner","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.25259\/IJDVL_886_19\/ref-12","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/ar3179","article-title":"Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus","volume":"12","author":"Daridon","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.25259\/IJDVL_886_19\/ref-13","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1182\/blood-2012-12-473744","article-title":"Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab","volume":"122","author":"Rossi","year":"2013","journal-title":"Blood"},{"key":"10.25259\/IJDVL_886_19\/ref-14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/ severe active systemic lupus erythematosus: Results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study","volume":"73","author":"Wallace","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_886_19\/ref-15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/art.39856","article-title":"Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: Results from two phase III randomized, double-blind, placebo-controlled trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_886_19\/ref-16","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: Current and future therapeutic strategies","volume":"10","author":"Didona","year":"2019","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_886_19\/ref-17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.coi.2005.04.005","article-title":"The role of APRIL and BAFF in lymphocyte activation","volume":"17","author":"Schneider","year":"2005","journal-title":"Curr Opin Immunol"},{"key":"10.25259\/IJDVL_886_19\/ref-18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1365-2133.2006.07305.x","article-title":"Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris","volume":"155","author":"Asashima","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.4103\/ijdvl.IJDVL_96_16","article-title":"High B-cell-activating factor levels in endemic Tunisian pemphigus","volume":"83","author":"Mejri","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.25259\/IJDVL_886_19\/ref-20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/01.EWX.0000542472.35180.f9","article-title":"Assessment of serum a proliferation-induced ligand level in patients with pemphigus vulgaris","volume":"15","author":"El-Eriny","year":"2018","journal-title":"J Egypt Womens Dermatol Soc"},{"key":"10.25259\/IJDVL_886_19\/ref-21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jdermsci.2006.12.008","article-title":"Increased serum levels of a proliferation-inducing ligand in patients with bullous pemphigoid","volume":"46","author":"Watanabe","year":"2007","journal-title":"J Dermatol Sci"},{"key":"10.25259\/IJDVL_886_19\/ref-22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/jid.2008.192","article-title":"B-cell-directed therapy for inflammatory skin diseases","volume":"129","author":"Nagel","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-23","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1111\/ajd.12615","article-title":"Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia","volume":"58","author":"Lee","year":"2017","journal-title":"Australas J Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-24","doi-asserted-by":"crossref","first-page":"AB141","DOI":"10.1016\/j.jaad.2016.02.555","article-title":"A new treatment for autoimmune blistering diseases-The efficacy of the Bruton's tyrosine kinase inhibitor PRN473 in canine pemphigus foliaceus","volume":"74","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-25","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2019.00978","article-title":"Current clinical trials in pemphigus and pemphigoid","volume":"10","author":"Izumi","year":"2019","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_886_19\/ref-26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1517\/14712598.2011.573476","article-title":"Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy","volume":"11","author":"Ramos","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.25259\/IJDVL_886_19\/ref-27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.25259\/IJDVL_886_19\/ref-28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4161\/mabs.3.5.16983","article-title":"Neonatal Fc receptor and IgG-based therapeutics","volume":"3","author":"Kuo","year":"2011","journal-title":"MAbs"},{"key":"10.25259\/IJDVL_886_19\/ref-29","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10875-010-9468-4","article-title":"Neonatal Fc receptor: From immunity to therapeutics","volume":"30","author":"Kuo","year":"2010","journal-title":"J Clin Immunol"},{"key":"10.25259\/IJDVL_886_19\/ref-30","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1007\/s00018-010-0318-6","article-title":"The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases","volume":"67","author":"Sesarman","year":"2010","journal-title":"Cell Mol Life Sci"},{"key":"10.25259\/IJDVL_886_19\/ref-31","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/14712598.2019.1559291","article-title":"Biological therapy of autoimmune blistering diseases","volume":"19","author":"Alaibac","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.25259\/IJDVL_886_19\/ref-32","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"10.25259\/IJDVL_886_19\/ref-33","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"10.25259\/IJDVL_886_19\/ref-34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1586\/1744666X.2016.1123092","article-title":"IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases","volume":"12","author":"vanBeek","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.25259\/IJDVL_886_19\/ref-35","first-page":"251","article-title":"Role of IgE in bullous pemphigoid: A review and rationale for IgE directed therapies","volume":"147","author":"Messingham","year":"2012","journal-title":"G Ital Dermatol Venereol"},{"key":"10.25259\/IJDVL_886_19\/ref-36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","article-title":"Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity","volume":"153","author":"vanBeek","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00403-017-1789-1","article-title":"IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: A systematic review","volume":"310","author":"Saniklidou","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"10.25259\/IJDVL_886_19\/ref-38","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-39","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1001\/archdermatol.2012.1604","article-title":"Successful treatment of bullous pemphigoid with omalizumab","volume":"148","author":"London","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and omalizumab for the treatment of bullous pemphigoid: A systematic review of the literature","volume":"20","author":"Kremer","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000452828","article-title":"Successful treatment of a bullous pemphigoid patient with rituximab who was refractory to corticosteroid and omalizumab treatments","volume":"9","author":"Bilgi\u00e7Temel","year":"2017","journal-title":"Case Rep Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1684\/ejd.2019.3499","article-title":"Dramatic exacerbation of bullous pemphigoid following rituximab and successful treatment with omalizumab","volume":"29","author":"Maglie","year":"2019","journal-title":"Eur J Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-43","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clim.2018.12.015","article-title":"IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid","volume":"198","author":"James","year":"2019","journal-title":"Clin Immunol"},{"key":"10.25259\/IJDVL_886_19\/ref-44","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/j.1365-2133.2011.10748.x","article-title":"Successful management of severe infant bullous pemphigoid with omalizumab","volume":"166","author":"Dufour","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-45","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/exd.13416","article-title":"Eosinophils as putative therapeutic targets in bullous pemphigoid","volume":"26","author":"Simon","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-46","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.coph.2018.12.007","article-title":"Pharmacological advances in pemphigoid","volume":"46","author":"Maglie","year":"2019","journal-title":"Curr Opin Pharmacol"},{"key":"10.25259\/IJDVL_886_19\/ref-47","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-48","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.jid.2017.05.017","article-title":"The Syk tyrosine kinase is required for skin inflammation in an in vivo mouse model of epidermolysis bullosa acquisita","volume":"137","author":"N\u00e9meth","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-49","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fimmu.2018.00249","article-title":"Whole-genome expression profiling in skin reveals Syk as a key regulator of inflammation in experimental epidermolysis bullosa acquisita","volume":"9","author":"Samavedam","year":"2018","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_886_19\/ref-50","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3389\/fimmu.2019.01089","article-title":"Skin barrier and autoimmunity-mechanisms and novel therapeutic approaches for autoimmune blistering diseases of the skin","volume":"10","author":"Stevens","year":"2019","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_886_19\/ref-51","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S142471","article-title":"Emerging treatment options for the management of pemphigus vulgaris","volume":"14","author":"Kridin","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"10.25259\/IJDVL_886_19\/ref-52","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/sj.jid.5700016","article-title":"Tolerance induction by the blockade of CD40\/CD154 interaction in pemphigus vulgaris mouse model","volume":"126","author":"Aoki-Ota","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-53","doi-asserted-by":"crossref","first-page":"e12696","DOI":"10.1111\/dth.12696","article-title":"Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus","volume":"31","author":"Tavakolpour","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_886_19\/ref-54","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: A systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.25259\/IJDVL_886_19\/ref-55","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.autrev.2014.12.002","article-title":"A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab","volume":"14","author":"Ahmed","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.25259\/IJDVL_886_19\/ref-56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/imt-2017-0104","article-title":"Rituximab in pemphigus","volume":"10","author":"Hebert","year":"2018","journal-title":"Immunotherapy"},{"key":"10.25259\/IJDVL_886_19\/ref-57","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): A prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_886_19\/ref-58","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.det.2018.12.003","article-title":"Treatment update of autoimmune blistering diseases","volume":"37","author":"Kridin","year":"2019","journal-title":"Dermatol Clin"},{"key":"10.25259\/IJDVL_886_19\/ref-59","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations by an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-60","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jaad.2014.05.071","article-title":"Successful use of rituximab in the treatment of childhood and juvenile pemphigus","volume":"71","author":"Vinay","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-61","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/ijd.12582","article-title":"Pemphigus herpetiformis: A case series and review of the literature","volume":"54","author":"Laws","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-62","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4103\/ijdvl.IJDVL_848_17","article-title":"Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: A retrospective single-center review of up to 68 months follow-up","volume":"86","author":"De","year":"2020","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.25259\/IJDVL_886_19\/ref-63","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1001\/jamadermatol.2013.6739","article-title":"Durable remission of pemphigus with a fixed-dose rituximab protocol","volume":"150","author":"Heelan","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-64","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2310\/7750.2014.14092","article-title":"Cost and resource use of pemphigus and pemphigoid disorders pre-and post-rituximab","volume":"19","author":"Heelan","year":"2015","journal-title":"J Cutan Med Surg"},{"key":"10.25259\/IJDVL_886_19\/ref-65","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_886_19\/ref-66","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaad.2015.11.030","article-title":"Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up","volume":"74","author":"Ahmed","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-67","doi-asserted-by":"publisher","first-page":"451","DOI":"10.4103\/0378-6323.163706","article-title":"Therapeutic potential of biosimilars in dermatology","volume":"81","author":"Gupta","year":"2015","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.25259\/IJDVL_886_19\/ref-68","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/exd.12331","article-title":"The need for markers and predictors of Rituximab treatment resistance","volume":"23","author":"Sitaru","year":"2014","journal-title":"Exp Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-69","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1074\/jbc.M114.593806","article-title":"Activatory and inhibitory Fc\u03b3 receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain","volume":"290","author":"Vaughan","year":"2015","journal-title":"J Biol Chem"},{"key":"10.25259\/IJDVL_886_19\/ref-70","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/ni.2939","article-title":"Type I and type II Fc receptors regulate innate and adaptive immunity","volume":"15","author":"Pincetic","year":"2014","journal-title":"Nat Immunol"},{"key":"10.25259\/IJDVL_886_19\/ref-71","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.autrev.2016.02.006","article-title":"Targeting Fc\u03b3Rs to treat antibody-dependent autoimmunity","volume":"15","author":"Yu","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.25259\/IJDVL_886_19\/ref-72","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: Mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"key":"10.25259\/IJDVL_886_19\/ref-73","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3389\/fimmu.2019.00481","article-title":"Targeting the antibody checkpoints to enhance cancer immunotherapy-focus on Fc\u03b3RIIB","volume":"10","author":"Teige","year":"2019","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_886_19\/ref-74","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00277-016-2731-x","article-title":"Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma\/leukemia","volume":"95","author":"Burkhardt","year":"2016","journal-title":"Ann Hematol"},{"key":"10.25259\/IJDVL_886_19\/ref-75","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3389\/fimmu.2019.02237","article-title":"Genetic variation in low-to-medium-affinity Fc\u03b3 receptors: Functional consequences, disease associations, and opportunities for personalized medicine","volume":"10","author":"Nagelkerke","year":"2019","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_886_19\/ref-76","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"key":"10.25259\/IJDVL_886_19\/ref-77","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1111\/bjd.15658","article-title":"Identification of factors associated with treatment refractoriness of oral lesions in pemphigus vulgaris","volume":"177","author":"Kumar","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-78","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/1523-1747.ep12460927","article-title":"Regional variation in the expression of pemphigus foliaceus, pemphigus erythematosus, and pemphigus vulgaris antigens in human skin","volume":"96","author":"Ioannides","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-79","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1349-7006.2006.00138.x","article-title":"Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab","volume":"97","author":"Takami","year":"2006","journal-title":"Cancer Sci"},{"key":"10.25259\/IJDVL_886_19\/ref-80","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1093\/rheumatology\/kev210","article-title":"The alternative CD20 transcript variant is not a surrogate marker for resistance to rituximab in patients with rheumatoid arthritis","volume":"54","author":"Gamonet","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.25259\/IJDVL_886_19\/ref-81","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/exd.12299","article-title":"Lack of expression of an alternative CD20 transcript variant in circulating B cells from patients with pemphigus","volume":"23","author":"Gamonet","year":"2014","journal-title":"Exp Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-82","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4103\/idoj.IDOJ_290_18","article-title":"Rituximab in pemphigus: Road covered and challenges ahead","volume":"9","author":"Vinay","year":"2018","journal-title":"Indian Dermatol Online J"},{"key":"10.25259\/IJDVL_886_19\/ref-83","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jaad.2015.10.051","article-title":"Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission","volume":"74","author":"Daneshpazhooh","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-84","first-page":"WC01","article-title":"Rituximab: A magic bullet for pemphigus","volume":"11","author":"Anandan","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"10.25259\/IJDVL_886_19\/ref-85","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jaad.2017.11.024","article-title":"Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single center","volume":"78","author":"Vinay","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-86","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/jdv.12678","article-title":"An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab","volume":"29","author":"Amber","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_886_19\/ref-87","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2133.2011.10663.x","article-title":"Low-dose rituximab is effective in pemphigus","volume":"166","author":"Horv\u00e1th","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-88","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1001\/jamadermatol.2019.3236","article-title":"Factors associated with complete remission after rituximab therapy for pemphigus","volume":"155","author":"Kushner","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-89","doi-asserted-by":"publisher","first-page":"810","DOI":"10.3389\/fimmu.2018.00810","article-title":"Ultra-low dosage regimen of rituximab in autoimmune blistering skin conditions","volume":"9","author":"Alaibac","year":"2018","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_886_19\/ref-90","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41598-017-17934-6","article-title":"Single, very low rituximab doses in healthy volunteers-A pilot and a randomized trial: Implications for dosing and biosimilarity testing","volume":"8","author":"Schoergenhofer","year":"2018","journal-title":"Sci Rep"},{"key":"10.25259\/IJDVL_886_19\/ref-91","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/ckj\/sfx038","article-title":"Infectious complications of rituximab therapy in renal disease","volume":"10","author":"Nixon","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.25259\/IJDVL_886_19\/ref-92","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-associated infections","volume":"47","author":"Gea-Banacloche","year":"2010","journal-title":"Semin Hematol"},{"key":"10.25259\/IJDVL_886_19\/ref-93","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/ijd.13140","article-title":"Literature-based immunization recommendations for patients requiring immunosuppressive medications for autoimmune bullous dermatoses","volume":"55","author":"Laniosz","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-94","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-95","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s12016-009-8153-y","article-title":"High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases","volume":"38","author":"Ishii","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.25259\/IJDVL_886_19\/ref-96","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3389\/fimmu.2019.01090","article-title":"High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease","volume":"10","author":"Hoffmann","year":"2019","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_886_19\/ref-97","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.intimp.2016.02.013","article-title":"First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up","volume":"34","author":"Ahmed","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"10.25259\/IJDVL_886_19\/ref-98","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1007\/s12325-017-0610-z","article-title":"Subcutaneous rituximab for the treatment of B-cell hematologic malignancies: A review of the scientific rationale and clinical development","volume":"34","author":"Davies","year":"2017","journal-title":"Adv Ther"},{"key":"10.25259\/IJDVL_886_19\/ref-99","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1001\/jamadermatol.2014.3674","article-title":"Intralesional rituximab in the treatment of refractory oral pemphigus vulgaris","volume":"151","author":"Vinay","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_886_19\/ref-100","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jaad.2011.01.029","article-title":"Sirolimus for acute pemphigus vulgaris: A case report and discussion of dualistic action providing for both immunosuppression and keratinocyte protection","volume":"65","author":"Grando","year":"2011","journal-title":"J Am Acad Dermatol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/biologics-in-autoimmune-bullous-diseases-current-scenario-2\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/biologics-in-autoimmune-bullous-diseases-current-scenario-2\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T17:24:32Z","timestamp":1725384272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/biologics-in-autoimmune-bullous-diseases-current-scenario-2\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":100,"alternative-id":["10.25259\/IJDVL_886_19"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_886_19","relation":{},"ISSN":["0378-6323"],"issn-type":[{"value":"0378-6323","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]},"article-number":"611"}}